Laboratorios Ojer Pharma, spin-off of the University of Navarra, recognized at the Quality Innovation Award 2025 (QIA)
The pharmaceutical business , born in the environment of the School of Pharmacy and Nutrition, has been recognized in the category Innovation in SMEs for a sustained release technology applied to dermatological treatments.
19 | 11 | 2025
Laboratorios Ojer Pharma, a spin-off of the University of Navarra, has been recognized as one of the eight winning initiatives in the national phase of the Quality Innovation Award (QIA) 2025, in the category Innovation in SMEs.
The distinction, awarded by the Nationalassociation of Centers Promoting Excellence (CEX), in partnership with the Spanish National Research committee (CSIC) and the Basque University System Quality Agency (UNIBASQ), has recognized the bioadhesive sustained release gel platform (GTP) developed by the company, a technology that optimizes the efficacy and safety of dermatological treatments in humans and animals.
In the words of Ojer Pharma's CEO, Carlos González Ojer, these gels "act as a matrix that releases the active ingredient in a controlled manner, favoring therapeutic compliance in both humans and animals and providing an optimal alternative to conventional treatments".
This year's edition of the QIAs received nearly one hundred entries from companies, technology centers, universities and public organizations from various autonomous communities.
Applied innovation originating at the School
Laboratorios Ojer Pharma was born in 2005 as a project staff of Carlos González Ojer that took shape and later developed in the School of Pharmacy and Nutrition. Since then, both entities have maintained a solid scientific and educational partnership . In fact, González Ojer himself combines the management of the company with professor as a professor in the Master's Degree in Drug research, development and Innovation at the School.
The spin-off is today a pharmaceutical company specialized in human and veterinary dermatology that focuses its activity on the development of innovative drugs and technologies based on sustained release bioadhesive gels, with the goal of improving the quality of life of patients through effective and safe solutions.
As González Ojer emphasizes, this recognition "highlights years of joint work between researchers, professionals in the sector and students, and reinforces our commitment to innovation that has a real impact on health".
International reference letter competition
The Quality Innovation Awards have been held annually since 2007 and goal topromote innovation and share best practices at an international level. After passing the national phase, the awarded projects will compete in an international phase, where organizations from different countries will decide the global winners of the QIA 2026, based on their impact, usefulness and differential character.
